分子别名（Synonym）
CD19,B4,CVID3,MGC12802
表达区间及表达系统（Source）
MABSol® Biotinylated Human CD19, Fc Tag, primary amine labeling (CD9-H8259) is expressed from human HEK293 cells. It contains AA Pro 20 - Lys 291 (Accession # P15391-1). It is the biotinylated form of Human CD19, Fc Tag (Cat. No. CD9-H5259).
Predicted N-terminus: Pro 20
Request for sequence
蛋白结构（Molecular Characterization）
This protein carries a human IgG1 Fc fragment at the C-terminus. The protein has a calculated MW of 56.3 kDa. The protein migrates as 60-90 kDa on a SDS-PAGE gel under reducing (R) condition due to glycosylation.
标记（Biotinylation）
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product.
蛋白标记度（Biotin:Protein Ratio)
Passed as determined by the HABA assay / binding ELISA.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
>95% as determined by SDS-PAGE.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳（SDS-PAGE）
Biotinylated Human CD19, Fc Tag, primary amine labeling DMF Filed on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
活性（Bioactivity）-ELISA
Immobilized Anti-Mouse FMC63 MAb at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD19, Fc Tag, primary amine labeling (Cat. No. CD9-H8259) with a linear range of 0.039-0.625 μg/mL (QC tested).
Protocol
Report
Immobilized a series of concentration of Biotinylated Human CD19, Fc Tag, primary amine labeling (Cat. No. CD9-H8259) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind FMC63 (Mouse IgG2a) 2 μg/mL (100 μL/well) with a linear range of 0.039-1.25 μg/mL (Routinely tested).
Protocol
文献引用（Citations）
Authors: Miller IC, Zamat A, Sun LK, et al.
Journal: Nature biomedical engineering 2021
Application: Flow cytometry
Co-stimulatory domains for use in genetically-modified cells
Authors: D Jantz, et al
Journal: US20190233500A1 2019
Application: Flow Cytometry
TREM1/Dap12-based CAR-T cells show potent antitumor activity
Authors: B Chen, et al
Journal: Immunotherapy 2019
Application: Flow Cytometry
Authors: MacLeod DT, et al.
Journal: Mol Ther 2017
Application: Flow Cytometry
背景（Background）
B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.
